Nuvation BioNUVB +3.60%33 Current Ratio is 7.44 as of Mar. 2026, which is 80% below its 10-year median of 36.74. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Nuvation Bio ranks better than 70.18% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Nuvation Bio's current ratio for the quarter that ended in Mar. 2026 was 7.44.
Nuvation Bio has a current ratio of 7.44. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Nuvation Bio's Current Ratio or its related term are showing as below:
NUVB'
s Current Ratio Range Over the Past 10 Years
Min: 6.95 Med: 36.74 Max: 83.19
Current: 7.44
During the past 6 years, Nuvation Bio's highest Current Ratio was 83.19. The lowest was 6.95. And the median was 36.74.
NUVB's Current Ratio is ranked better than 70.18% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs NUVB: 7.44
Nuvation Bio (NYSE:NUVB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Nuvation Bio Current Ratio Related Terms
Nuvation Bio Current Ratio Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUVB vs VRDN, STOK, ATAI: Current Ratio Comparison
For the Biotechnology subindustry, Nuvation Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Current Ratio distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NUVB) has a Current Ratio of 7.44 as of Mar. 2026. This is 80% below median its historical median of 36.74. Over the past decade, Nuvation Bio's Current Ratio has ranged from 6.95 to 83.19. According to the industry distribution chart, Nuvation Bio ranks #421 out of 1412 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Nuvation Bio's Current Ratio too high?
Nuvation Bio's current Current Ratio of 7.44 is 80% below median its 10-year median of 36.74. Over the past 10 years, this metric has ranged from a low of 6.95 to a high of 83.19. The Biotechnology industry median Current Ratio is 3.90. Nuvation Bio's value of 7.44 is 90.8% above this industry median. Based on the distribution chart, Nuvation Bio ranks #421 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Current Ratio compare to VRDN and STOK?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #421 out of 1412 companies for Current Ratio. This puts Nuvation Bio in the upper half of its industry. The industry median Current Ratio is 3.90. Nuvation Bio's value of 7.44 is 90.8% above this benchmark. Historically, Nuvation Bio's own Current Ratio has ranged from 6.95 to 83.19 over the past decade. While the company's 10-year median is 36.74 vs. the industry median of 3.90, Nuvation Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current Current Ratio of 7.44 is 90.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current Current Ratio is 7.44, which is 80% below median its own 10-year median of 36.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Current Ratio of 7.44. The current Current Ratio is 7.44, which is 80% below median its 10-year median of 36.74 and 90.8% above the Biotechnology industry median of 3.90. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Current Ratio is 7.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score
Get the complete analysis for NUVB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
